We are live on ! Find out more
VYGR icon

Voyager Therapeutics

69 hedge funds and large institutions have $58.6M invested in Voyager Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 32 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

134% more call options, than puts

Call options by funds: $272K | Put options by funds: $116K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3.51% less ownership

Funds ownership: 62.14%58.63% (-3.5%)

12% less funds holding

Funds holding: 7869 (-9)

39% less capital invested

Capital invested by funds: $96.8M → $58.6M (-$38.2M)

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

50% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 32

Holders
69
Holders Change
-9
Holders Change %
-11.54%
% of All Funds
1.21%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
16
Reduced
32
Closed
17
Calls
$272K
Puts
$116K
Net Calls
+$156K
Net Calls Change
+$185K

VYGR Hedge Fund Activity: Q3 2021 in Review

69 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q3 2021, worth a combined $58.6M — down 39% from $96.8M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of VYGR and 9 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 16 added.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $1.45M. The largest seller was Citadel Advisors, cutting an estimated $2.03M.

  • 69 institutional investors held Voyager Therapeutics (VYGR) as of Q3 2021, down from 78 in Q2 2021.
  • Funds reported $58.6M of Voyager Therapeutics stock for Q3 2021, down 39% quarter-over-quarter.
  • 9 funds opened new Voyager Therapeutics positions in Q3 2021 and 17 closed out, a net change of -8 holders.
  • The largest Voyager Therapeutics buyer in Q3 2021 was EcoR1 Capital, an estimated $1.45M added.
  • The largest Voyager Therapeutics seller in Q3 2021 was Citadel Advisors, an estimated $2.03M sold.

Based on aggregated 13F filings for Q3 2021.